[1]Patent:US4251528,1981,A
[1]Patent:US4251528,1981,A
[1]ChemicalBiologyandDrugDesign,2010,vol.75,p.381-391
[1]ChemicalBiologyandDrugDesign,2010,vol.75,p.381-391
Title: Aldo-keto reductases protect lung adenocarcinoma cells from the acute toxicity of B[a]P-7,8-trans-dihydrodiol.
Journal: Chemical research in toxicology 20120113
Title: Synthesis and antimycobacterial evaluation of novel Phthalazin-4-ylacetamides against log- and starved phase cultures.
Journal: Chemical biology & drug design 20100401
Title: Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
Journal: Proteins 20030201
Title: A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat.
Journal: Journal of pharmaceutical and biomedical analysis 20020401
Title: Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
Journal: Journal of medicinal chemistry 20000323
Title: Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice.
Journal: Anticancer research 19990101
Title: Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Journal: Journal of medicinal chemistry 19850701
Title: Ward WH, et al. Ponalrestat: a potent and specific inhibitor of aldose reductase. Biochem Pharmacol. 1990 Jan 15;39(2):337-46.
Title: Bresson E, et al. The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium. J Clin Endocrinol Metab. 2011 Jan;96(1):210-9.
Title: Calcutt NA, et al. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia. 2004 Apr;47(4):718-24.
